Medical device and healthcare company Abbott arranged to have their canine and kid patients treated for patent ductus ...

A randomized controlled trial evaluates if selective early treatment of patent ductus arteriosus reduces death or bronchopulmonary dysplasia at 36 weeks in extreme preterm babies. Findings from the ...

This section presents medications that are known to potentially lead to 'Patent ductus arteriosus' as a side effect. It's important to note that mild side effects are quite common with medications.

SHOULD closure of a patent ductus arteriosus with reversal of flow be attempted? If so, how can the high surgical mortality hitherto reported 1–3 be reduced? An attempt is made to answer these ...

Patent ductus arteriosus (PDA) is a congenital cardiac defect that occurs when the ductus arteriosus fails to close. The result is a persistent communication between the aorta and pulmonary artery, ...

Please provide your email address to receive an email when new articles are posted on . Abbott announced that the FDA approved a closure device for the treatment of premature babies with patent ductus ...

Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.

Patent Ductus arteriosus is the second commonest congenital birth defect of the heart and can cause heart failure; however majority of these defect close spontaneously after birth. Patent Ductus ...